iBio, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
iBio disclosed a corporate presentation (dated September 2026) outlining its pipeline: IBIO-610 (Activin E antibody, IND filing expected 2H 2026, Phase 1 1H 2027), IBIO-600 (myostatin antibody in Phase 1 SAD as of June 2026, interim data 1Q 2027), IBIO-800 (myostatin × Activin A bispecific, IND 1H 2027, targeting PH-HFpEF and obesity), plus early-stage amylin and undisclosed programs. As of June 30, 2026, the company had $88.0M in cash/equivalents, 64.3M shares outstanding, and 87.3M shares issuable on pre-funded warrants at $0.001/share; cash runway extends to Q4 FY 2028.
Why this rating
Pipeline progress and cash sufficiency are positive, but standard preclinical/early clinical updates. Against $57.5M market cap, $88M cash is substantial; however, no new partnerships, financing, or clinical readouts occurred—only disclosure of known strategy. Moderate business significance.
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.